



Company name: JMS Co., Ltd.  
 Name of representative: Hiroaki Okukubo, President and Representative Director  
 (Securities code: 7702; Prime Market of Tokyo)  
 Inquiries: Ryuji Katsura, Executive Director, Head of Corporate  
 Affairs Division  
 (Telephone: +81-82-243-5844)

## Notice Regarding Differences between Consolidated Financial Forecast and Actual Results for the Fiscal Year Ended March 31, 2023, and Extraordinary Losses in Non-Consolidated Financial Settlement.

Announcement of the following discrepancy between the consolidated financial forecast for the fiscal year ended March 31, 2023 (April 1, 2022 - March 31, 2023) announced on November 4, 2022 and the actual results for the same period disclosed today. Additionally, announcement of the following loss on valuation of stocks of subsidiaries has been recorded as an extraordinary loss in non-consolidated financial results for the fiscal year ended March 31, 2023.

### 1. Difference between consolidated financial forecast and actual results for the fiscal year ended March 31, 2023 (April 1, 2022 - March 31, 2023)

(Unit: million yen)

	Net sale	Operating profit	Ordinary profit	Profit attributable to owners of parent	Earnings per share
Forecast previously announced (A)	62,000	400	400	200	8.18 yen
Actual results announced today (B)	63,740	724	586	281	11.50 yen
Difference (B - A)	1,740	324	186	81	
Difference (%)	2.8	81.2	46.6	40.5	
<Reference> Actual results for previous fiscal year ended March 31, 2022	58,169	980	1,126	826	33.83 yen

#### (Explanation for the difference)

Net sales exceeded the previous forecast by 1,740 million yen (2.8%) due to strong sales of Apheresis kits and AV Fistula Needles for North America, with recovery in demand, as well as increased yen equivalent value due to yen depreciation. Profits exceeded the previous forecast in any of operating income, ordinary income, and profit attributable to owners of parent due to the effect of increased sales, which absorbed to some extent the effect of soaring prices of raw materials and electricity costs, and the reduction of selling, general and administrative expenses.

---

2. Recording of loss on valuation of stocks of subsidiaries in non-consolidated financial statements

Our consolidated subsidiary, JMS HEALTHCARE PHILIPPINES, INC. has been steadily expanding its business since it started operations in 2016 as a new plant in the Republic of the Philippines. However, due to the recent COVID-19, the effect of the rapid yen depreciation and other factors, there has been a delay in achieving the business plan that was initially envisioned.

As a result of the above, the Company decided to recognize impairment loss and to record an extraordinary loss of 1,434 million yen as loss on valuation of stocks of subsidiaries in its non-consolidated financial statements.

Loss on valuation of stocks of subsidiaries is recorded only in non-consolidated financial statements due to the elimination in consolidated closing process, so there is no effect on the consolidated results.

END